Q-omics provides the consensus-scored SUMO2P14 profile across patient tissues and cancer cell-line models. SUMO2P14 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SUMO2P14 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, SUMO2P14 RNA expression shows 10,950 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, KIRC, and LSCC as cancer lineages where SUMO2P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUMO2P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUMO2P14 survival associations across molecular data types. SUMO2P14 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUMO2P14 RNA expression–survival associations across cancer types. High SUMO2P14 expression shows unfavorable associations in LIHC, THYM, BLCA, READ, ESCA and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SUMO2P14 RNA expression.
This table summarizes SUMO2P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SUMO2P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUMO2P14 shows higher tumor expression in KIRC, UCEC and KIRP. The KIRC box plot shows higher SUMO2P14 RNA expression in tumor versus normal tissue (log2 FC = +0.024, t-test p = .041).
This table shows molecular features associated with SUMO2P14 in patient tissues and cancer cell lines. In patient samples, SUMO2P14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
